Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis

Trial Details

NCT ID

NCT07263425

Phase

PHASE2

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir

Locations (sample)

• Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

• Histologically or cytologically confirmed HER-2 positive breast cancer (immunohistochemistry indicates HER-2 3+ and/or fluorescence in situ hybridi…
• Diagnosed with breast cancer with leptomeningeal metastasis based on cerebrospinal fluid cytology combined with central nervous system function and…
• The patient has an Ommaya reservoir implanted or is eligible for implantation
• Adequate bone marrow and liver and kidney function reserves: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, hemoglobin ≥ 9…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.